FDA OKs vitamin C trial for cancer

January 12, 2007

Federal approval of a clinical trial on intravenous vitamin C as a cancer treatment lends credence to alternative cancer care, U.S. researchers said.

Cancer Treatment Centers of America said it won Food and Drug Administration approval to begin the trial, a move the Illinois-based hospital group said adds credibility to its research into alternative methods for cancer medical care, the Chicago Tribune said Thursday. It is the first FDA-approved trial for CTCA.

Just a few patients will be eligible, said Christopher Lis, the firm's vice president of research and development.

"Only patients who have exhausted all other conventional treatment options are eligible to receive the therapy," Lis said.

The first phase will be to determine the optimal dose for the patients and to learn whether the treatment is safe and can be tolerated, Lis said. Additional studies over several years would be needed to demonstrate whether it is effective.

Earlier studies conducted with vitamin C supplements administered orally did not to demonstrate a clinical benefit to cancer patients.

Cancer Treatment Centers, with facilities in Illinois, Pennsylvania and Oklahoma, provides traditional and alternative treatment for cancer patients.

Copyright 2007 by United Press International

Explore further: New era in precision medicine for pancreatic cancer

Related Stories

New era in precision medicine for pancreatic cancer

March 23, 2017

The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research ...

Researchers gain insight into breast cancer drug resistance

March 24, 2017

Breast cancer's ability to develop resistance to treatment has frustrated researchers and physicians and has thwarted even the latest and greatest targeted therapies. For example, after researchers identified a disease pathway ...

Pembrolizumab shows promise in treatment of mesothelioma

March 20, 2017

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School ...

Recommended for you

'Jumonji' protein key to Ewing's sarcoma rampage

March 24, 2017

By the time Ewing's Sarcoma is diagnosed, primarily in teens and young adults, it has often spread from its primary site to other parts of the body, making it difficult to treat. A University of Colorado Cancer Center study ...

In a sample of blood, researchers probe for cancer clues

March 24, 2017

One day, patients may be able to monitor their body's response to cancer therapy just by having their blood drawn. A new study, led by bioengineers at UC Berkeley, has taken an important step in that direction by measuring ...

Is there a link between telomere length and cancer?

March 23, 2017

Telomeres are regions of repetitive DNA at the end of human chromosomes, which protect the end of the chromosome from damage. Whilst shorter telomeres are hypothesized biological markers of older age and have been linked ...

Three-pronged approach is key to precision medicine

March 23, 2017

Combining genetic information from a patient's tumor cells with three-dimensional cell cultures grown from these tumors and rapidly screening approved drugs can identify the best treatment approaches in patients for whom ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.